GC Green Cross Wellbeing Completes Phase 3 Dosing of "Lainekju"
Multicenter Clinical Trial Concludes at 18 Domestic Institutions
Establishing Evidence for Intravenous Administration and High-Dose Dosing
GC Green Cross Wellbeing announced on April 23 that it has completed dosing for all participants in the Phase 3 clinical trial of Lainekju, a hydrolyzed human placenta extract formulation, in patients with chronic liver disease.
This clinical trial was conducted as a multicenter study to evaluate dose escalation and the addition of new administration routes. A total of 18 domestic institutions, including Severance Hospital, participated. The main focus was on assessing the safety and efficacy of the high-dose intravenous injection method.
With dosing completed for all participants, the clinical trial has now begun analyzing the primary evaluation indicators. After obtaining the results, the company plans to apply for a change in approval with the Ministry of Food and Drug Safety.
Lainekju is currently administered via intramuscular and subcutaneous injections. If the intravenous administration method is added, it is expected that the choice of administration route can be tailored to the patient's condition.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A representative of GC Green Cross Wellbeing stated, "Completion of dosing in this Phase 3 clinical trial marks a strategic turning point to further enhance the market competitiveness of Lainekju," adding, "Based on the clinical data obtained through dose escalation, we will broaden treatment accessibility and continue to strengthen our market competitiveness."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.